Loading market dashboard
Voyageur Pharmaceuticals Ltd.
VYYRFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Calgary, Alberta, Canada – June 5, 2026 – TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur "), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased to announce that, further to its news releases dated May 1, 2026, and May 28, 2026, it has closed its non-brokered private placement (the " Offering "), and has issued (i) 30,935,000 units (" Units ") at a price of $0.10 per Unit, for total proceeds raised from the issuance of Units of $3,093,500, and (ii) 15,931,486 flow-through units (" FT Units " and, together with the Units, the " Securities ") at a price of $0.12 per FT Unit, for total proceeds raised from the issuance of FT Units of $1,911,778.32, for total aggregate gross proceeds of $5,005,278.32. This closing represents the final closing of the Offering. Accordingly, the Company does not intend to complete any further tranches or issue any additional Securities under the Offering.
Calgary, Alberta, Canada – May 1, 2026 - TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur "), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, announces that it has terminated the non-brokered private placement previously announced on March 25, 2026.
